AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Editas Medicine Stock Outperforms Medical Sector Amid Earnings Growth
ByAinvest
Tuesday, May 13, 2025 11:40 am ET1min read
Editas Medicine (EDIT) is a stock in the Medical sector that has outperformed its peers this year, with a 21.3% gain compared to a 4.2% average decline for the sector. The stock has a Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has increased 7.8% in the past quarter. Another Medical stock, Arbutus Biopharma (ABUS), has also outperformed the sector with a 2.5% year-to-date return and a Zacks Rank of #2 (Buy).
Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have both demonstrated strong performance in the first quarter of 2025, outperforming their respective sectors. Editas Medicine, a genome editing company, reported a quarterly loss of $0.43 per share, which was a significant improvement over the Zacks Consensus Estimate of $0.51 per share. This represents a 15.69% earnings surprise, marking the second time in the last four quarters that Editas has surpassed consensus EPS estimates [1].The company's revenue for the quarter ended March 2025 was $4.66 million, a substantial increase of 385.21% compared to the Zacks Consensus Estimate. This compares to year-ago revenues of $1.14 million. Editas has shown resilience in the face of market challenges, with a 14.2% gain since the beginning of the year compared to the S&P 500's decline of -3.8% [1].
Arbutus Biopharma, a biopharmaceutical company focused on infectious diseases, reported a 2.5% year-to-date return, outperforming the sector. The company has a Zacks Rank of #2 (Buy), indicating positive future performance expectations. Arbutus has a robust pipeline, including AB-729, a subcutaneously-delivered RNA interference product candidate, and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication [2].
Both companies have shown strong performance and positive outlook, with Editas Medicine's Zacks Consensus Estimate for full-year earnings increasing by 7.8% in the past quarter. Investors should keep a close eye on the earnings outlook and management commentary for both companies to gauge future performance [1].
References:
[1] https://www.nasdaq.com/articles/editas-medicine-edit-reports-q1-loss-tops-revenue-estimates-1
[2] https://quantisnow.com/company/ABUS
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet